Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Corteva

Is Wall Street Bullish or Bearish on Corteva Stock?

Corteva has underperformed the S&P 500 over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Barchart

Buy This Dividend Yielding and 130% 5-year Return Stock After the Corn Harvest in October

Equity traders often overlook seasonality (market cycles). Commodity traders are well aware of the significance that seasonal patterns play. Here is an opportunity for equity traders to capitalize on a seasonal pattern in the corn market that has helped to create an astonishing 130% 5-year return for this company. As…

Barchart

What You Need to Know Ahead of Corteva's Earnings Release

Corteva is expected to release its fiscal third-quarter earnings next month, and analysts project a double-digit increase in loss.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

How To Spot Good Value Stocks In A Sea Of Noise

Explore why traditional value investing often falls short and how catalysts can transform undervalued stocks into lucrative investments.

Barchart

Is Corteva Stock Outperforming the S&P 500?

Corteva has recently outperformed the S&P 500, and Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Bullish on Corteva Stock?

Corteva has lagged the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

What to Expect From Corteva's Next Quarterly Earnings Report

Corteva is expected to release its second-quarter earnings later this month, and analysts project a double-digit earnings growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Genetically modified crops aren't a solution to climate change, despite what the biotech industry says

The European Commission launched a proposal in July 2023 to deregulate a large number of plants manufactured using new genetic techniques.

The Conversation

UN human rights experts express alarm over PFAS pollution in North Carolina

Evidence of Chemours-operated plant contaminating region is ‘alleged human rights violations’, say experts appointed by council

The Guardian - US

Climate rules are coming for corporate America

U.S. regulators are finalizing rules that will make publicly traded companies disclose information about climate change. Other jurisdictions have been announcing similar requirements.

WEKU

Chemical companies’ PFAS payouts are huge – but the problem is even bigger

3M, DuPont, Chemours and Corteva have agreed settlement in the billions for polluting drinking water with ‘forever chemicals’

The Guardian - US

2 Agtech Stocks Benefitting From the Growing Global Population

As the global population skyrockets, the world will demand more food but have less farmland. Here are 2 companies actively trying to solve this issue.

Barchart

Companies reach $1.18 billion deal to resolve claims from 'forever chemicals' water contamination

Three chemical manufacturing companies have reached a deal to resolve complaints of polluting many U.S. drinking water systems with compounds known as PFAS

The Independent UK

Top US chemical firms to pay $1.2bn to settle water contamination lawsuits

Dupont, Chemours and Corteva agree deal and 3M also reportedly considering $10bn settlement to avoid trial due to start on Monday

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

The 9 Best Materials Stocks to Buy Now

The short-term outlook for materials stocks is low, but these nine names could be diamonds in the rough.

The Guardian - AU

How big pesticide reaches into every element of rural life in Australia

Multinational chemical firms subsidise agronomists, provide scholarships, sponsor farm safety programs and even fund the pesticide regulator

The Hindu

Corteva upbeat on India operations, to ramp up footprint, headcount

Trials are under way for seed-applied treatment for paddy, product registration awaited

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Factors Likely To Decide Nu Skin's (NUS) Fate In Q2 Earnings

Nu Skin Enterprises, Inc. NUS is likely to display year-over-year declines in the top and bottom lines when it reports second-quarter 2022 earnings on Aug 4.

Benzinga

Analyzing Corteva's Short Interest

Corteva's (NYSE:CTVA) short percent of float has fallen 18.52% since its last report. The company recently reported that it has 7.92 million shares sold short, which is 1.1% of all regular shares that are available for trading.

Benzinga

Peering Into Corteva's Recent Short Interest

Corteva's (NYSE:CTVA) short percent of float has risen 9.72% since its last report. The company recently reported that it has 5.73 million shares sold short, which is 0.79% of all regular shares that are available for trading.

Benzinga

What 7 Analyst Ratings Have To Say About Corteva

Within the last quarter, Corteva (NYSE:CTVA) has observed the following analyst ratings:

Benzinga

Expert Ratings for Corteva

Over the past 3 months, 6 analysts have published their opinion on Corteva (NYSE:CTVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.

Benzinga

Corteva: Q1 Earnings Insights

Corteva (NYSE:CTVA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 05:00 PM. Here's what investors need to know about the announcement. Earnings Corteva beat estimated earnings by 18.29%, reporting an EPS of $0.97 versus an estimate of $0.82.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.